Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX)
Amneal Pharmaceuticals hits 52-week and all-time high, driven by strong social engagement and positive news. Company faces margin pressure and patent lawsuits.
About Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal Pharmaceuticals, Inc. Class A Common Stock is a publicly traded pharmaceutical company.
Amneal Pharmaceuticals, Inc. Class A Common Stock uses the ticker $AMRX for trading. Listed in the Stocks category.
Insights
- Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) social dominance is up 500% from the previous week.
- Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) Galaxy Score™ is up 43.33% from the previous week.
- Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) engagements is up 101.41% from the previous week.
- Amneal Pharmaceuticals, Inc. Class A Common Stock Price hit a 52-Week high of $15 for the hour
- Amneal Pharmaceuticals, Inc. Class A Common Stock Price hit an all time of $15 for the hour
Price: $14.80
Price 24-Hour Time-Series Raw Data
The stock price hit a 52-week and all-time high, likely driven by positive social sentiment, FDA approvals, and analyst upgrades. A slight decline may indicate profit-taking or broader market influences.
24-Hour: 1.16% 7-Day: 3.02% 30-Day: 10.51%
1-Year High: $14.80 on 2026-02-13
1-Year Low: $7 on 2025-04-10
AltRank: [-----]
AltRank 24-Hour Time-Series Raw Data
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is currently AltRank #1,373 based on combined combined social and market metrics
Daily Average: [-----]
[--] Week: [-----] [----]
[--] Month: [-----] +359
[--] Months: [-----] +73
[--] Year: [-----] +651
1-Year High: [-----] on 2026-02-04
1-Year Low: [--] on 2025-08-23
Galaxy Score: [-----]
Galaxy Score 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [--]
[--] Week: [--] +13
[--] Month: [--] +8
1-Year High: [--] on 2025-11-04
1-Year Low: [--] on 2025-10-09
Engagements: [------] (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: [------]
Daily Average: [------]
[--] Week: [-------] +101%
[--] Month: [-------] -51%
[--] Months: [---------] +76%
[--] Year: [---------] +777%
1-Year High: [-------] on 2025-08-20
1-Year Low: [--] on 2026-01-03
Engagements by network (24h): X: [---] Instagram: [--] YouTube: [------] Reddit: [--] TikTok: [--]
Mentions: [--] (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: [--]
Daily Average: [--]
[--] Week: [--] -20%
[--] Month: [---] +19%
[--] Months: [---] -48%
[--] Year: [-----] +119%
1-Year High: [---] on 2025-06-28
1-Year Low: [--] on 2025-10-26
Mentions by network (24h): X: [--] Instagram: [--] YouTube: [--] Reddit: [--] TikTok: [--]
Creators: [--] (24h)
Creators 24-Hour Time-Series Raw Data
[--] unique social accounts have posts mentioning Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) in the last [--] hours which is down 17% from [--] in the previous [--] hours
Daily Average: [--]
[--] Week: [--] -32%
[--] Month: [---] +20%
[--] Months: [---] -64%
[--] Year: [-----] +179%
1-Year High: [---] on 2025-06-28
1-Year Low: [--] on 2025-10-26
The most influential creators that mention Amneal Pharmaceuticals, Inc. Class A Common Stock in the last [--] hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @tunemusicalmoments | [--] | [---------] | [--] | [------] |
| @Tautilas | [--] | [-----] | [--] | [---] |
Sentiment: 64%
Sentiment 24-Hour Time-Series Raw Data
Current Value: 64%
Daily Average: 88%
[--] Week: 100% no change
[--] Month: 59% -41%
[--] Months: 59% -41%
[--] Year: 59% -8%
1-Year High: 100% on 2025-02-20
1-Year Low: 25% on 2025-03-16
Most Supportive Themes:
- FDA Approvals: (40%) Amneal Pharmaceuticals has received several FDA approvals for its products, including epinephrine injection, albuterol sulfate inhalation aerosol, and iohexol injection. These approvals expand access to critical medicines and demonstrate the company's innovation.
- Analyst Upgrades: (20%) Analysts from firms like Piper Sandler and Barclays have upgraded Amneal Pharmaceuticals, with price targets indicating positive future outlooks. This suggests confidence from financial experts in the company's performance.
- Positive Phase [--] Results: (10%) Amneal Pharmaceuticals announced positive interim Phase [--] ELEVATE-PD results for CREXONT, a treatment for Parkinson's Disease. This indicates progress in clinical trials and potential for new therapeutic offerings.
Most Critical Themes:
- Margin Pressure: (30%) Despite strong revenue growth, Amneal Pharmaceuticals experienced only a 1% increase in adjusted EBITDA, indicating significant margin pressure. This suggests that while sales are increasing, profitability is not keeping pace.
- Patent Infringement Lawsuits: (25%) Amgen Inc. has filed patent infringement lawsuits against Amneal Pharmaceuticals and others over proposed biosimilar versions of its drugs. This legal challenge could impact the company's market share and revenue from these products.
Social Dominance: 0.0009863433714907312%
Social Dominance 24-Hour Time-Series Raw Data
Current Value: 0.0009863433714907312%
Daily Average: 0.00444%
[--] Week: 0.0018% +0.0015%
[--] Month: 0.0016% +0.0009000000000000001%
[--] Months: 0.0016% -0.0017%
[--] Year: 0.0016% -0.0036%
1-Year High: 0.032% on 2025-06-29
1-Year Low: 0.0003% on 2025-10-26
Market Dominance: 0.00528%
Market Dominance 24-Hour Time-Series Raw Data
Current Value: 0.00528%
Daily Average: 0%
1-Year High: 0.211% on 2026-02-06
1-Year Low: 0.00528% on 2026-02-16
Market Cap: $4,658,858,474
Market Cap 24-Hour Time-Series Raw Data
Current Value: $4,658,858,474
Daily Average: $3,631,986,256
[--] Week: $4,658,858,474 +2.10%
[--] Month: $4,658,858,474 +11%
[--] Months: $4,658,858,474 +58%
1-Year High: $4,658,858,474 on 2026-02-13
1-Year Low: $2,908,374,401 on 2025-08-18
Top Amneal Pharmaceuticals, Inc. Class A Common Stock Social Posts
Top posts by engagements in the last [--] hours
Showing a maximum of [--] top social posts without a LunarCrush subscription.
"1402_INKA $ADI $ALGM $AMAT $AMRX $BCRX $BKR $CDNS $CENX $CHRW $CLMT $CMCSA $ENTG $EVRG $FANG $GERN $KMB $LNT $LSCC $MDB $MDLZ $MKSI $NXPI $SBUX $SHOO $SSRM $TXN $VOD $VRNS $VSAT $XEL"
X Link @Tautilas 2026-02-16T10:17Z [----] followers, [---] engagements
"Gaspers story: Strength family and moving forward Gaspers experience with CREXONT is his own and may not reflect the experience of every patient. Most common side effects include nausea and anxiety. For some people CREXONT may cause falling asleep during daily activities. Individual results will vary. Always speak with your doctor to determine if CREXONT may be right for you. Only a healthcare provider can assess your condition and guide you to the appropriate treatment options. INDICATION CREXONT (carbidopa and levodopa) extended-release capsules is a prescription medication for the"
YouTube Link @amnealpharma 2025-09-24T13:47Z [----] followers, 4.6M engagements
"CREXONT (carbidopa and levodopa) extended-release capsules has transformed innovation into duration CREXONT Mechanism of Action (MOA) For patients and caregivers. For the rst time in Parkinsons disease an oral therapy was designed to target where levodopa is best absorbed the proximal small intestine-making CREXONT the oral CD/LD formulation with the longest-lasting LD plasma concentration * ** References: *Exact site and duration of absorption are unknown. **Based on the time that LD plasma levels were above 50% of Cmax. [--]. Hauser RA Espay AJ Ellenbogen AL et al. IPX203 vs immediate-release"
YouTube Link @amnealpharma 2025-08-12T18:39Z [----] followers, 8.7M engagements
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing